Drug class
Reversible acetylcholinesterase inhibitor; potassium-channel blocker and cholinergic neuromodulator
Mechanism of action
Reversibly inhibits acetylcholinesterase, increasing acetylcholine at central and peripheral cholinergic synapses. It also blocks voltage-gated potassium channels, prolonging neuronal action potentials and enhancing presynaptic calcium entry and neurotransmitter release.
General use cases
- Symptomatic treatment of acquired mononeuropathies and polyneuropathies in adults.
- Adjunctive symptomatic treatment of myasthenia gravis and selected bulbar dysfunction during recovery after brainstem ischaemic stroke.
- Symptomatic treatment of mild-to-moderately severe Alzheimer’s disease and intestinal atony, where authorised under the revised European product information. Other previously listed uses were restricted or removed following the EMA review in September 2026.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
